DexCom, Inc.  

(Public, NASDAQ:DXCM)   Watch this stock  
Find more results for Steven R. Altman´┐Ż
92.23
+2.67 (2.98%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 89.70 - 92.39
52 week 47.92 - 103.29
Open 90.33
Vol / Avg. 882,846.00/994,160.00
Mkt cap 7.92B
P/E     -
Div/yield     -
EPS -0.79
Shares 83.43M
Beta 0.32
Inst. own 96%
Aug 2, 2016
Q2 2016 DexCom Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 2, 2016
Q2 2016 DexCom Inc Earnings Release - 4:00PM EDT - Add to calendar
Jul 22, 2016
DexCom Inc to Discuss Clinical Chemistry and Clinical Toxicology Devices Panel Conference Call
Jun 15, 2016
DexCom Inc at William Blair Growth Stock Conference
Jun 7, 2016
DexCom Inc at Jefferies Healthcare Conference
May 27, 2016
DexCom Inc Annual Shareholders Meeting (Estimated)
May 19, 2016
DexCom Inc Annual Shareholders Meeting
May 11, 2016
DexCom Inc at Bank of America Merrill Lynch Health Care Conference
May 4, 2016
DexCom Inc at Deutsche Bank Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -16.52% -14.33%
Operating margin -16.52% -14.20%
EBITD margin - -11.52%
Return on average assets -26.04% -24.17%
Return on average equity -34.05% -31.88%
Employees 1,212 -
CDP Score - -

Address

6340 Sequence Dr
SAN DIEGO, CA 92121-4356
United States - Map
+1-858-2000200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. It had received Conformite Europeene Marking (CE Mark) approval for its fourth generation continuous glucose monitoring system, the DexCom G4 system, enabling commercialization of the DexCom G4 system. DexCom SHARE enables users of its G4 PLATINUM System to have their sensor glucose information remotely monitored by their family or friends. The G4 PLATINUM Receiver with Share uses a secure wireless connection via Bluetooth Low Energy (BLE) between a patient's receiver and a mobile application on the patient's iPhone to transmit glucose information.

Officers and directors

Terrance H. Gregg Executive Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Kevin R. Sayer President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Lanny Jess Roper Chief Financial Officer, Senior Vice President
Age: 51
Bio & Compensation  - Reuters
Jorge A. Valdes Executive Vice President, Chief Technology Officer
Age: 54
Bio & Compensation  - Reuters
Andrew K. Balo Executive Vice President - Clinical, Regulatory and Quality
Age: 68
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard B. Doubleday Executive Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
Steven R. Pacelli Executive Vice President - Strategy and Corporate Development
Age: 44
Bio & Compensation  - Reuters
Jeffrey C. Moy Senior Vice President - Operations
Age: 55
Bio & Compensation  - Reuters
John D. Lister General Manager - Europe, Middle East and Africa
Age: 41
Bio & Compensation  - Reuters
Mark G. Foletta CPA Lead Independent Director
Age: 55
Bio & Compensation  - Reuters